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Abstract
Background:  Methylation of CpG dinucleotides is a fundamental mechanism of epigenetic
regulation in eukaryotic genomes. Development of methods for rapid genome wide methylation
profiling will greatly facilitate both hypothesis and discovery driven research in the field of
epigenetics. In this regard, a single molecule approach to methylation profiling offers several unique
advantages that include elimination of chemical DNA modification steps and PCR amplification.
Results: A single molecule approach is presented for the discernment of methylation profiles,
based on optical mapping. We report results from a series of pilot studies demonstrating the
capabilities of optical mapping as a platform for methylation profiling of whole genomes. Optical
mapping was used to discern the methylation profile from both an engineered and wild type
Escherichia coli. Furthermore, the methylation status of selected loci within the genome of human
embryonic stem cells was profiled using optical mapping.
Conclusion: The optical mapping platform effectively detects DNA methylation patterns. Due to
single molecule detection, optical mapping offers significant advantages over other technologies.
This advantage stems from obviation of DNA modification steps, such as bisulfite treatment, and
the ability of the platform to assay repeat dense regions within mammalian genomes inaccessible to
techniques using array-hybridization technologies.
Background
DNA methylation is a major epigenetic mechanism of
gene regulation in higher eukaryotes. DNA methylation
can be defined as the addition of a methyl group to the
base of a nucleotide by DNA methyltransferases [1,2]. In
prokaryotes, DNA methyltransferases operate in tandem
with restriction enzymes as a part of a defense mechanism
against invading viral DNA. Prokaryotic DNA methyla-
tion protects native DNA from cleavage by endogenous
restriction enzymes, thus creating a defense mechanism
against invading viral DNA [3]. In higher eukaryotes,
DNA methylation acts to protect the genome, by silencing
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the expression of retroviruses [4]; however, it is gene reg-
ulation mediated by DNA methylation that is of principal
interest.
Since the methylation of cytosine at position C5 in the
context of cytosine guanine dinucleotides plays a signifi-
cant biological role in higher eukaryotes, its detection
forms the primary focus of our research. In higher eukary-
otes, CpG dinucleotides are often clustered together form-
ing CpG islands [5] that frequently coincide with
upstream regulatory elements and promoters of genes. A
consequence of methylation of upstream promoter
regions is repression of targeted genes. Transcription
repression occurs by either a direct obstruction of the
major grove [6] or via a methylation binding protein [7]
mechanism. In fact, methylation of CpG dinucleotides
and CpG islands is the major mechanism for imprinting
in eukaryotes. Methylation profiles are mediated by
mechanisms associated with factors such as age, nutrition,
disease, or mutational events that may induce pathogenic
changes in gene expression. Both hypo- and hyper-meth-
ylation are known to play a role in the onset of oncogenic
disease [8] by either activating oncogenes or by silencing
tumor suppressor genes. Abnormal DNA methylation
plays a role in a myriad of disease, with a notable example
being schizophrenia [9,10].
The development of single molecule approaches for the
discernment of genome wide methylation profiles that
also obviate traditional chemical modification steps
points the way towards creation of new high-throughput
platforms. Current methods for analysis of DNA methyla-
tion require chemical treatment of DNA bases that do not
readily query genomic repeat elements [11]. Bisulfite PCR
[12] is the current "gold standard" method for assaying
DNA methylation. During bisulfite treatment, cytosines
are deaminated forming uracil while methylated cytosines
remain unmodified. These changes can then be tested by
PCR amplification of selected loci. To probe the methyla-
tion status of specific nucleotides, PCR products are
cloned and sequenced. Post bisulfite sequence is com-
pared to wild type, where unmethylated nucleotides
appear as C to T point mutations. While bisulfite sequenc-
ing is an excellent technique for sampling specific loci
with an underlying hypothesis in hand, the computa-
tional complexity of designing PCR primers and multiple
requisite steps make it impractical for comprehensive
genome analysis. Also due to inherent incompatibility of
PCR analysis with regions of genomic repeats, it is difficult
to use bisulfite PCR to analyze repeat regions of genomes,
where high-resolution knowledge of methylation states
may provide important biological insights.
Currently, methods combining bisulfite treatment of
DNA with "BeadArray" hybridization are being used to
assay the methylation state of selected loci within the
human genome [13]. The BeadArray platform alleviates
the inherent computational complexity of differential
PCR primer design and obviates the need for hundreds of
PCR reactions; however, such analysis does not interro-
gate many classes of genomic repeats. Another promising
approach is the direct sequencing of bisulfite PC ampli-
cons using 454 sequencing [14]. The 454 sequencing
approach eliminates the need for PCR product cloning.
Thousands of individual sequence reads are generated for
each PCR product, compared to tens of reads generated
using conventional bisulfite sequencing. The current
methods for discernment of genomic methylation have
been reviewed in great detail elsewhere [15,16].
In contrast to bisulfite PCR which is time consuming,
costly and difficult to use on a large scale when coupled
with PCR analysis, optical mapping offers many advan-
tages for comprehensive methylation profiling. It is an
established single molecule platform for investigation of
whole genomes. Optical mapping has been used for the
construction of complete physical maps of numerous bac-
terial, plant and human genomes [17-31] (for an in depth
description of optical mapping see [32]).
The OM system creates high-resolution physical maps of
genomes based on ordered restriction maps of individual
DNA molecules. Briefly, individual high molecular weight
(~500 kb) DNA molecules are unraveled and arrayed
upon positively charged glass surfaces using a microflu-
idic device [33]. After deposition, molecules are restriction
digested, then stained with a fluorochrome dye and
finally imaged by automated fluorescence microscopy
(Figure 1). "Daughter" restriction fragments remain
bound to the surface retaining original order allowing
construction of ordered restriction maps from individual
"parental" molecules. This step is accomplished through
automated image processing and analysis of individual
DNA molecules, which are converted into "molecular bar
codes" based on the distances (kb) as measured by inte-
grated fluorescence intensity between sites of restriction
enzyme cleavage. The molecular bar code represents a
unique identification "tag" for each individual molecule
used by map alignment algorithms [34-36] and software
for construction of whole genome physical maps.
Since optical mapping uses genomic DNA substrates,
which retain inherent CpG methylation patterns, we rea-
soned that methylation sensitive restriction enzymes
would profile such patterns of DNA modification on a
whole genome basis. Because methyltransferases and
restriction enzymes operate in tandem in bacteria, the
Escherichia coli genome was used as a facile model system
for methylation profiling by optical mapping. Since most
restriction enzymes will not cleave methylated cognateBMC Molecular Biology 2008, 9:68 http://www.biomedcentral.com/1471-2199/9/68
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sequences, modified sites are directly detected as missing
restriction sites, thereby obviating chemical modification
steps as part of this detection process. More importantly,
by selecting appropriate restriction enzymes, we can bias
the investigation of specific repeated elements within a
mammalian genome, such as CpG islands or LINES [37],
by keying an enzyme's cognate sequence towards cleavage
within chosen elements.
As such, our detection strategies use: (i) solely methyla-
tion sensitive restriction enzymes, or (ii) a combination
of methylation sensitive and insensitive enzymes within
the same reaction. This enzyme combination, especially
for mammalian genomes, produces interpretable bar
codes through added flexibility in how single molecule
restriction maps are created and then analyzed. Consider
that "consensus" maps, or contigs–constructed from
merging multiple, overlapping optical maps (single mol-
ecule)–are assessed for methylation states by comparison
against a sequence based in silico map ("reference map"; a
restriction map computationally constructed from
sequence data). Consequently, scheme (ii) partitions
genomic placement of such contigs from consideration of
methylation status by anchoring contigs using only those
restriction patterns created by the methylation insensitive
enzyme. After contigs are placed against a reference map,
methylation status is derived by comparing the nucleotide
locations of methylation sensitive cleavage sites (cuts)
within a contig to the corresponding in silico restriction
map features of a reference genome. In other words,
absence or presence of those restriction sites queried by
the methylation-sensitive enzyme tabulates their modifi-
cation state.
Strategy (i), described above, is applied for the detection
of the methylation profile of both an engineered and a
wild type E. coli. The results firmly validate this strategy for
small genomes. We then employed strategy (ii), designed
for analysis of complex genomes, for reporting CpG meth-
ylation of a mid passage (p44) human embryonic stem
cell line H1. Generating only modest coverage of optical
maps across the entire human genome, over 90 sites of
DNA methylation were detected across Ch 9 in regions
showing usable coverage by optical maps. These findings
illustrate the feasibility of using a single molecule
approach for de novo discovery of methylation patterns
presented by complex genomes.
Results
Strategy for detection of methylation sites using only a 
methylation-sensitive enzyme
We analyzed optical maps generated by a methylation
sensitive restriction enzyme (NheI {G^CTAGC}) for
revealing genome-wide patterns of DNA methylation
(strategy (i)) engendered by AluI methylase (AGCMeT) on
Optical mapping system Figure 1
Optical mapping system. An overview of the optical map-
ping system. A; Large, genomic DNA molecules are elon-
gated and arrayed as 15 mm long stripes onto positively 
charged surfaces using a microfluidic device; a green line 
depicts one channel (48 total). B; After restriction digestion 
and staining, an automated fluorescence microscope scanner 
("Genome Zephyr"; [D]) serially acquires overlapping image 
frames along each of the 48 stripes laid down by the micro-
fluidic device. ChannelCollect software flattens and overlaps 
images maintaining sub-pixel registration; ~8/170 overlapped 
image frames from one channel are shown. White "threads" 
are individual DNA molecules; blue boxes indicate each ~100 
μm-wide frames. C; Machine vision (Pathfinder [32,33]) iden-
tifies molecules and constructs ordered restriction maps for 
each molecule; integrated fluorescence intensity measure-
ments estimate mass of daughter restriction fragments in 
kilobasepairs. D; An optical mapping station known as 
Genome Zephyr; pictures show microscope, fiber-optic illu-
mination, computer controlled stage. The insert shows the 
optical mapping software interface–ChannelCollect. The user 
identifies the start and end coordinates of the first and last 
channel on a surface. Further channels are identified by the 
software. Imaging and data processing are fully automated.
A B
C
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E. coli genomic DNA molecules. By engineering such
methylation sites within a genome, in contrast to assess-
ing naturally occurring methylation sites, we generate a
list of known modified sites. Virtually all sites that block
cleavage with NheI can be experimentally identified (see
Figures 2 and 3).
Selection of appropriate methylase/restriction enzyme
pairs is facilitated by the fact that most restriction enzymes
do not cleave DNA if their recognition, or cognate
sequence is methylated (in some cases, this is dependent
on whether cytosines or adenines are modified). Given a
list of genomic locations that are expected to be enzymat-
ically methylated in vitro, calculated from sequence infor-
mation, we then select a restriction enzyme that will
optimally detect expected restriction maps (Figure 2); fac-
tors considered include the average size and distribution
of restriction fragments produced after DNA methylation.
Nominally, restriction maps constructed from individual
molecules must present a sufficient density of restriction
sites for confident map construction or alignment against
a reference map. Since AluI DNA methylase targets the
cytosine in the sequence AGCT, we selected a restriction
enzyme that partially overlaps with the AluI methylation
sites. (If overlap is complete, no restriction maps will be
created.) The cognate sequence of the restriction enzyme
NheI (G^CTAGC) overlaps with AluI methylation sites at
the sequences: AGCMeTAGC  and  GCTAGCMeT, and at
these NheI sites we expect to observe no cleavage. Data
acquired from sufficient numbers of randomly sheared E.
coli  DNA molecules allow redundant coverage of the
entire genome, thereby assaying all overlapping sites of
NheI/AluI methylase revealed as missing NheI cuts in the
alignment of the NheI consensus optical map to the in sil-
ico sequence map.
Detection of AluI methylation sites in the E. coli genome
We evaluated strategy (i) across the entire E. coli genome
using AluI methylase treated DNA, followed by optical
mapping with NheI. AluI methylation modifies 13,335
sites in the E. coli genome, and it is expected to block
cleavage at approximately 30% (51/158) of the NheI
cleavage sites (see explanation provided below). A data set
consisting of 1,377 NheI/AluI methylase E. coli optical
maps (cleaved single molecules) was created (Methods).
From the raw data set, we selected 631 maps larger than
550 kb as the most informative for the construction of the
de novo optical map spanning the entire E. coli genome.
This filtering process compensated for the relatively large,
42.70 kb, average fragment size observed in this data set
by ensuring sufficient density of restriction cleavage sites
across all considered molecules spanning the entire E. coli
genome [24].
Given the experimentally derived average fragment size
(42.70 kb), we formulated preliminary measures of DNA
methylation. In the absence of AluI methylation, NheI
optical maps are expected to have an average fragment
size of 29.36 kb. Thus, the apparent digestion efficiency of
methylated DNA was about 69%, so that ~30% of NheI
cleavage sites were blocked by AluI methylation, or par-
tially digested. The final assembled contig contained 176
optical maps indicating a 28% contig rate (Figure 3 panels
B and C); the modest contig rate was due to the large aver-
age fragment size [24] of the map data set. Contig rate is
calculated by dividing the number of maps in a contig by
the total number of maps submitted for contig construc-
tion (176/631 × 100% = 28% for this data set).
Following assembly, the de novo optical map contig was
aligned with the in silico map based on the E. coli sequence
with the assumption of no methylation (Figure 3 panel D;
subset of alignment shown). Based on this alignment, we
were able to confidently identify 43 NheI sites as missing
cuts blocked by AluI methylation (see Additional file 1).
Given the known nucleotide locations of AluI methyla-
tion and NheI cleavage, we had expected 51 NheI sites to
be blocked by AluI methylation. Of the 8 sites that were
not readily identified, all but one represented small
restriction fragments (2 kb and less). Three of the above
instances showed irregularly sized fragments in the align-
ment. Of the 5 fragments not detected, 1 was not detected
due to an assembly error, 3 were too small to be detected
(~150 bp), and 1 small fragment (1.7 kb) was in a low
coverage area where detection was not possible. Of course
given more coverage, some of the above problems can be
ameliorated.
Strategies for detection DNA methylation using restriction  enzymes Figure 2
Strategies for detection DNA methylation using 
restriction enzymes. Detection of methylation patterns 
using a single methylation sensitive restriction enzyme. 
Knowledge of expected restriction sites, from an in silico 
map, in the absence of methylation, locates methylation sites 
revealed through actual restriction digestion. A; In silico 
restriction map; cleavage sites are shown as vertical red bars. 
B; A hypothetical distribution of DNA methylation sites; 
green bars. C; Composite restriction map (A + B) incorpo-
rating blocking effects from the overlap of restriction with 
methylation sites; location of missing restriction sites caused 
by overlap (blue circles).BMC Molecular Biology 2008, 9:68 http://www.biomedcentral.com/1471-2199/9/68
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Dcm methylation profiling of E. coli strain K-12 MG1655
Given the positive results of genomic methylation profil-
ing reported above on a synthetically methylated E. coli
genome, the same methylation profiling strategy (i) was
chosen to evaluate an E. coli strain bearing endogenous
methylation sites. For this experiment, we optically
mapped the E. coli strain K-12 MG1655, positive for Dcm
methylase [38], which is a modification system methylat-
ing the internal cytosine in the recognition sequence
CCWGG, where W is A or T. There are a total of 12,042
Dcm sites in the genome, and a portion of these sites are
detected using the methylation sensitive restriction
enzyme StuI, which cleaves AGG^CCT in E. coli at an aver-
age frequency of 7.66 kb. The two possible sites of Dcm
StuI overlap that would block StuI cleavage include
CCMeAGGCCT and AGGCCMeTGG (Figure 4 panel A).
A data set of 6,637 StuI optical maps was created for deter-
mining the Dcm methylation/StuI profile of E. coli K-12
MG1655. These optical maps were then pairwise aligned
to the StuI in silico map of E. coli allowing selection of the
700 top scoring molecules for assembly (see Methods).
This filtering step reduced the computational complexity
and accelerated map assembly when using data sets boast-
ing densely spaced restriction sites on mapped molecules.
The final contig comprises 469 maps (Figure 4 panel B),
indicating a 67% contig rate and an average fragment size
of 11.75 kb.
The StuI (Dcm) contig map was aligned to the in silico StuI
map using a map assembler [39,40]. We identified 128
StuI restriction sites as being methylated, assuming block-
age from overlapping and adjacent methylation, by scor-
Profiling of E. coli AluI methylation sites by NheI restriction mapping Figure 3
Profiling of E. coli AluI methylation sites by NheI restriction mapping. A; Overlaps between sites of NheI (red) 
restriction enzyme cleavage and AluI (blue) methylation blocking cleavage. B; NheI de novo optical map contig of AluI methyl-
ated E. coli, containing 176 maps. Outer red circle shows genome coordinates (kb) with internal arcs representing 176 maps; 
individual restriction fragments within each map are denoted by alternating colors; and grey radial lines demarcate restriction 
fragments within the contig map (next to the genome coordinates–red circle). The origin of the optical map does not coincide 
with the start of the published sequence, because the optical map was assembled de novo. C; An enlarged section (~960 kb) of 
the de novo NheI optical map contig. Colored blocks represent individual restriction fragments with their respective sizes (kb) 
marked above. D; Detailed comparison of the optical map shown in (C) against the corresponding in silico NheI map. NheI 
cleavage sites are shown as vertical bars; red bars show cleavage sites observed in the optical map. NheI sites overlapping with 
AluI methylation (absent in the optical map) are shown as blue vertical bars with a blue circle denoting blocking; below, the 
sequences around 3 NheI restriction sites are shown, two of which overlap AluI methylation sites.
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ing a missing cut (in relation to the in silico map) in the
optical contig map. Following the process used for the
characterization of the methylation status of NheI restric-
tion sites, we compared our experimentally determined
StuI methylation profile to in silico sequence prediction.
The E. coli genome contains 606 StuI cleavage sites, and
138 of these are expected to be blocked by Dcm methyla-
tion. Our methylation profiling results are in close agree-
ment with this analysis. All but 10 sites were identified
(128/138), and the 10 sites that were not all consist of
small (< 2 kb), poorly detected, restriction fragments (see
Additional file 2). One site was later identified as a mass
increase; thus the number of undetected sites is 9.
Exploring the human methylome
We then evaluated the methylation detection capabilities
of optical mapping within the human genome, using
strategy (ii) requiring one restriction enzyme for barcod-
ing and a second for revealing methylation patterns. A set
of optical maps was generated for the human embryonic
stem cell line H1 (passage 44), using the restriction
enzymes SwaI (ATTTÂAAT) for barcoding and EagI
(C^CGCCG) for detection of methylated restriction sites
(Figure 5). SwaI (barcoding) is an intrinsically CMepG
methylation insensitive restriction enzyme cleaving the
human genome at an average frequency of ~15 kb, while
EagI action is affected by methylation. In the absence of
methylation, EagI cleaves human DNA producing restric-
tion fragments with an average size of 32 kb. Not surpris-
Discernment of an in vivo methylation profile in E. coli Figure 4
Discernment of an in vivo methylation profile in E. coli. A; Overlap between sites of Dcm methylation and StuI cleavage. 
Dcm methylation and StuI cleavage sites are shown on top. The two overlaps between Dcm methylation (blue box) and StuI 
cleavage (red text) both block cleavage. B; The de novo optical map contig of MG1655 dcm+ strain of E. coli, assembled from 469 
StuI maps. Outer red circle indicates the size of the contigs, individual restriction fragments are denoted with alternating colors 
and grey lines. The origin of the optical map does not coincide with the start of the published sequence, because the optical 
map was assembled de novo. C; A representative section (~430 kb) of the de novo StuI optical map contig of dcm+ E. coli. Alter-
nating color blocks represent individual restriction fragments with their respective sizes (in kb) marked above the blocks. D; 
Comparison of in silico StuI map to de novo (C) Dcm+ E. coli optical map contig. StuI cleavage sites are represented as vertical 
bars. Red bars indicate cleavage sites observed in the de novo map. StuI sites overlapping with Dcm methylation (absent in the 
optical map) are shown as a blue vertical bar with a blue circle. Below are two examples of local sequence showing overlap 
between DNA cleavage and methylation sites and one example of local sequence showing no overlap.
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ingly given its CG-rich cognate sequence, EagI targets CpG
islands, often multiply cleaving small CpG islands pro-
ducing sub-microscopic restriction fragments. It is of sig-
nificant interest that EagI targets about 78% of the 27,437
CpG islands (21,287/27,437). EagI cleaves the human
genome at 89,473 sites (assuming no methylation).
About half of the CpG islands (14,008/27,437) contain
single EagI cuts, while another 7,279 of these targeted
islands comprise multiple cleavage sites (CpG island sta-
tistics taken from Santa Cruz genome browser).
Ideally, the two-enzyme optical maps would be assem-
bled into a genome-wide restriction map from which the
methylation pattern of the genome would be inferred.
Because our assembly algorithm does not support two-
enzyme maps, we employed the following scheme.
Briefly, two-enzyme optical maps are aligned to in silico
two-enzyme maps of the human genome; maps that align
are then stripped from the scaffold and independently
assembled into contigs. The consensus maps from such
contigs are then aligned back to in silico map (reference
map) (Figure 5, panel A). This alignment supports eluci-
dation of methylation patterns, in ways paralleling strat-
egy (i), from comparison of experimentally derived EagI
restriction sites (consensus maps) against the human ref-
erence map.
Given the above synopsis of our analysis scheme, EagI and
SwaI cleavage are conveniently merged together, both
during sequential digestion (Methods) and for methyla-
tion profiling, since pervasive CpG methylation greatly
attenuates the number of cleavable EagI restriction sites. It
is important to note that this tact enables confident place-
ment of serially digested molecules (SwaI/EagI), using just
Profiling methylation sites in the human genome Figure 5
Profiling methylation sites in the human genome. Optical mapping tabulations of hyper- and hypomethylation across 
human Ch 9. A; Optical mapping findings of hypomethylation (16 – red marks) and hypermethylation (75 – blue marks) are 
shown aligned to an in silico SwaI restriction map (gold and black horizontal lines) of entire human Ch 9 (Build 35, hg17; 140 
Mb). Optical maps constructed from a dual SwaI, EagI digestion and then overlapped forming contigs (purple boxes) are shown 
aligned to the in silico SwaI (methylation insensitive) map. B; Image of a single human DNA molecule (~400 kb) contained in the 
contig (469 kb) depicted in D; C, E; Detailed EagI (green vertical lines on track), SwaI (yellow vertical lines below line) in silico 
map of respective regions of human genome with blue (hypermethylation) and red (hypomethylation) dots showing methyla-
tion sites identified by optical mapping. Blue boxes represent genes, and green boxes show CpG islands. D, F; EagI, SwaI optical 
map contig with the restriction fragments size scaled and represented by staggered gold boxes. Contig D and F respectively 
span chromosome 9: Build 35, hg 17; start 96,297,748 bp, end 96,766,284 bp (D); start 118,802,475 bp, end 119,384,765 bp (F). 
G; An expanded view of a methylation call adjacent with Illumina findings showing nucleotide composition; red nucleotides 
show a hypomethylated EagI site with surrounding sequence (black). The CpG dinucleotide reported as hypomethylated by 
Illumina is bracketed [CG].
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SwaI restriction patterns on the human reference map. As
such, our analysis readily considers cleaved EagI sites as
"extra cuts," or modeled errors [41], appearing within a
SwaI restriction map after comparison against the human
reference map. Consequently, EagI restriction sites,
reflecting lack of methylation, are identified by their inter-
section with an EagI (in silico) human reference map,
which is overlaid upon the SwaI resource. Based on these
analysis guidelines, we developed several optical map
alignment approaches, described below, for building map
data sets supporting methylation profiling of the human
genome.
Optical maps, using a combination of SwaI and EagI
digestion, are aligned to the human reference map using
three complementary approaches (Methods): (a) pairwise
alignment against an in silico SwaI map for capturing
maps from heavily methylated regions with few EagI cuts;
(b) pairwise alignment against the SwaI map with relaxed
penalties for extra cuts (errors) for capturing maps from
unmethylated loci; and (c) alignment against a SwaI/EagI
in silico reference map for capturing maps from those
genomic regions with below average densities of SwaI
sites, but densely populated by available EagI sites.
We chose chromosome 9 for detailed analysis (Figure 5).
Our data set contained 731 optical maps that aligned to
chromosome 9 using at least one of the above approaches
(a, b, and/or c). Following assembly, the molecules
formed 30 contigs, of which 21 aligned back to in silico ref-
erence map. The 21 aligned contigs were assembled from
54 molecules and spanned 13.348 Mb. The genomic
regions covered by these contigs contained 244 EagI sites.
From the analysis of cleaved vs. uncleaved SwaI restriction
sites tabulated on the set of aligned optical maps, we esti-
mated the digest rate for SwaI as being about 85%. Since
these very same DNA molecules were also cleaved with
EagI under similar conditions, we reasoned that the EagI
and SwaI digest rates were closely linked. Accordingly,
estimation of EagI digestion rate allows confident assess-
ment of methylation status using the analysis described
below.
Since extra cut errors are random events and are only
modestly observed in optical maps, these characteristics
are leveraged for revealing unmethylated EagI restriction
sites within contigs. Consider that the probability of an
extra cut error occurring within a given interval of a
mapped molecule is 1-e-Nx; where N is the rate of extra cuts
per Mb (usually estimated to be 3) and x is the interval in
kb [34,35]. Using this analysis we identified 15 extra cuts
(0.01 < p < 0.00001) in the consensus maps within 2 kb
of an EagI site. These unmethylated loci contained 27 EagI
sites (see Additional file 3) and all except 1 were located
within CpG islands.
Since missing cut errors that are due to partial digestion
are prevalent in optical maps, identification of methylated
sites is more complex, and we deal with this issue by the
development of analysis leveraging the clustered cleavage
pattern shown by EagI in CpG islands. Accordingly, when
several EagI cuts are in close proximity to each other,
detection of methylation status in such clusters is actually
enhanced because there are multiple opportunities for
scoring cleavage events bounded by the spatial resolution
of light microscopy. Consider that the maximum resolu-
tion of light microscopy corresponds to ~600 bp of DNA
(~0.2 μm; fully stretched), so that a cluster of EagI cuts
within a 600 bp region is imaged as one merged cleavage
event. (Of course, this detection advantage also obscures
the methylation status of closely spaced CpGs. Also, mol-
ecules are typically stretched to about 80% of their poly-
mer contour length, and tiny restriction fragments tend to
desorb from the surface, so that "merged" cleavage events
include a greater span of about 2 kb.) Given an 85% digest
rate, the probability of having no cuts within a cluster of
n EagI cut sites is (1–0.85)n. We then identify methylated
EagI sites (p < 0.0005) located in areas containing multi-
ple EagI sites in close proximity (~2 kb) to each other that
also do not show any corresponding cuts in the optical
maps. In this way, we identified 12 such loci, containing
a total of 55 EagI sites (Additional file 4). Essentially, this
analysis allows confident calls by trading deep map cover-
age at a given genomic location for consideration of cleav-
age sites that are clustered.
The analysis of non-clustered (independent), methylated
EagI sites follows a different strategy. Given the previously
discussed SwaI and EagI digest rate of 85%, we designed
data filters requiring a minimum depth of 2 molecules for
calling methylation status; this analysis identified 68
methylated EagI sites (p < 0.0225) (see Additional file 4),
with 6 sites located within CpG islands (Figure 5, panels
B through F). Within this region we found that 27 out of
150 characterized EagI sites were cleaved, inferring an
apparent methylation rate of 80%. The above rate is in
agreement with the estimated rate of CpG methylation in
the human genome [13,42]. Unmethylated CpG dinucle-
otides are localized primarily to CpG islands with only
~35% of the islands being methylated in stem cells [43].
In our findings unmethylated loci are largely associated
with CpG islands while the methylated loci are located
outside of CpG islands (see Additional files 3 and 4).
To further validate our methods, we intersected data from
a recent (bead) microarray survey of human stem cell
methylation [43] with our findings. A locus common to
both datasets was further confirmed by bisulfite PCR. For
example, the promoter region of the DBC1 gene contains
a CpG island with 3 EagI cut sites. This locus is repre-
sented by 3 probes on the Illumina methylation beadBMC Molecular Biology 2008, 9:68 http://www.biomedcentral.com/1471-2199/9/68
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array [43]. Corresponding optical mapping data show
that one of the EagI sites located in the CpG island associ-
ated with the DBC1 promoter is cleaved, indicating
hypomethylation. The Illumina results in the DBC1 locus
(Illumina probe DBC1 1179) report the hypomethylation
(14% methylation level) of the CpG dinucleotide (ch 9:
119,211,696 bp; build 35, hg 17) that is directly adjacent
to the cleaved EagI site at (ch 9: 119,211,697 bp) (Figure
5, panel G). Our analysis also reports the adjacent EagI
site as being hypomethylated. We developed primers for
bisulfite PCR analysis of this locus, followed by cloning
and sequencing (Methods). The sequencing results con-
firmed that the EagI restriction enzyme site (119,211,697
bp) is unmethylated (11 of 11 clones) in the H1 p44
human embryonic stem cell genome (Table 1). These data
also demonstrate that all C's in the DBC1 sequence shown
in Table 1 are unmethylated.
Discussion and conclusion
We conclude that direct analysis of single genomic DNA
molecules is a viable means for genome wide, de novo
methylation profiling, based on our analysis of optical
mapping data from several E. coli systems, engineered and
wild, and a partial map of the human genome. Although
restriction endonucleases are simple, reliable reagents for
discernment of methylation patterns, their use on a whole
genome basis has been limited for lack of complementary
analysis systems for fully exploiting the practical advan-
tages they intrinsically represent–methylation status at
cognate sites directly revealed by cleavage without the use
of damaging chemical modification steps, or amplifica-
tion. In this regard, the optical mapping system, based on
the high-throughput analysis of ordered restriction maps,
offers whole genome methylation profiling capabilities
working from unmodified, unamplified genomic DNA
molecules that directly pinpoint cleavage events across
genomes. PCR amplification, however, does in theory
allow the analysis of any genomic locus, but practical con-
siderations–primer design and number of ampli-
cons–often limit comprehensive analysis of entire
genomes.
Furthermore, optical mapping readily profiles repeat-
strewn regions of mammalian genomes posing formida-
ble challenges for techniques using both amplification
and hybridization steps. On the other hand, optical map-
ping-based profiling is limited by those methylation sites
interrogated by a given restriction enzyme; however, we
have shown here that judicious choice of enzymes (SwaI/
EagI) ensures significant sampling of critical genomic ele-
Table 1: Bisulfite sequencing of the DBC1 locus
F primer GTA GGG TGT GTT TAT GT
R primer AAA AAA CTC TTA CTT CAT TCT
dbc CCTGAGTGTT TCTGGGGCGG CAGGTGTTTC CACGGCCG [CG]
7f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
7r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
18f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
18r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
4f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
4r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
12f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
12r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
3f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
3r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
2f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
2r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
16f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
16r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
13f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
13r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
6f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
6r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
8f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
8r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
10f TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
10r TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
......... ......... ......... .........
diff TTTGAGTGTT TTTGGGGTGG TAGGTGTTTT TATGGTTGTG
Sequences (forward and complement of reverse directions) of 11 bisulfite PCR product clones, aligned to the reference (top sequence). The EagI 
site in the DBC1 promoter is in red, data point from Illumina is bracketed. Both are shown to be unmethylated in our sample.BMC Molecular Biology 2008, 9:68 http://www.biomedcentral.com/1471-2199/9/68
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ments, such as CpG islands, despite very modest coverage
of the entire human genome by this data set. Additional
map coverage and other enzyme pairs targeting additional
genomic elements (i.e., LINES) would greatly augment the
scope of our human methylation profiling approach. This
scope is limited by the size of restriction fragments pro-
duced by a selected enzyme. Such limitations arise
because small restriction fragments are not uniformly
detected, so that their occurrence limits enzyme choice
and spatial resolution of methylation patterns. However,
if the algorithm used for the detection of DNA methyla-
tion presented in this paper is combined with map data
using the recently published optical barcoding system
[44] – using direct labeling in place of restriction digestion
– the limitations imposed on the method by enzyme
choice will be largely alleviated.
In many ways, the work we have presented here resembles
classical "footprinting" approaches, where nuclease
action is attenuated by the occurrence of protein-DNA
complexes as assayed by gel electrophoresis. Instead, our
findings show the footprint detection of modified DNA
sites. As such, we envision genomic footprinting of tran-
scription factors and other DNA binding proteins using
the approaches we have presented, and those we will
develop around the recently published DNA barcoding
approach [44] using nicking restriction enzymes and
fluorochrome labeling in place of the assessment of
restriction fragments. This new approach would likely
complement the capabilities of the Cognate Site Identifier
[45] technique by use of genomic targets fully presenting
native patterns of DNA modification and comprehen-
sively addressable genomic repeats. Lastly, we also envi-
sion that mammalian genomes will be profiled by optical
mapping for both methylation sites and structural vari-
ants (Copy Number Variants) [31] through analysis of
deep single molecule data sets revealing altered patterns
of genomic structure and DNA modification.
Methods
Bacterial culture strains and preparation of genomic DNA
E. coli genomic DNA agarose inserts [46] were prepared
from a culture grown overnight in a shaker using LB
media. To remove excess EDTA and null proteinase K
activity, inserts were washed five times, the first time being
overnight, in TE (10 mM Tris, 1 mM EDTA; pH 8.0) and
supplemented with 1.0 mM phenylmethylsulfonyl fluo-
ride (PMSF). Following wash steps, inserts were melted at
78°C for 5 minutes, and then treated with β-agarase
(NEB; 110 μl TE + 1 unit of β-agarase per 20 μl of agarose)
solution at 42°C for 4 hr.
Methylation of genomic DNA
E. coli genomic DNA inserts that have been washed in TE
were treated with 20 units of AluI methylase (NEB) in a
total buffer volume of 200 μl (including the 80 μl insert)
supplemented with 0.5 μl of NEB stock S-adenosyl-
methionine (SAM) overnight at 37°C. The efficiency of
the methylation reaction was tested with an "in-tube"
restriction digest, followed by gel electrophoresis, show-
ing that the cleavage activity of the AluI restriction enzyme
was significantly inhibited (data not shown).
Mammalian genomic DNA preparation
Human embryonic stem cell line H1 was cultured in a
feeder cell independent media according to published
protocol [47]. Upon reaching passage 44 cells were har-
vested and frozen in storage media (growth media supple-
mented with DMSO).
To prepare genomic DNA for optical mapping, aliquots of
1 × 106 cells were thawed on ice. Following thawing, cells
were washed twice with PBS. Liquid lysates of genomic
DNA were prepared by diluting hES cells in a solution of
0.1 M EDTA and 10 mM EGTA, pH 8.5, supplemented
with 1 μg/ml of Proteinase K, at concentrations ranging
from 10 to 200 cell/μl. Following dilution the lysates were
heated to 50°C for 1 hr, and then incubated at 37°C over-
night. Lysates were then stored at 4°C. Lysates containing
25–50 cell/μl yielded the best results.
Bisulfite treatment of genomic DNA
Bisulfite conversion of human genomic DNA was per-
formed using the EZ DNA methylation kit (Zymo
Research, Orange CA [catalog # D5001]), according to
manufacturer's instructions.
Bisulfite PCR
50 ng of bisulfite converted genomic DNA was used per
PCR reaction using DNA taq polymerase and buffers from
the Expand Long Template PCR system (Roche Applied
Science, Indianapolis IN (catalog # 11 681 834 001)). The
following primers were used for amplification of the
bisulfite treated DBC1 locus: forward primer GTA GGG
TGT GTT TAT GT, reverse primer AAA AAA CTC TTA CTT
CAT TCT. The primers were designed using the BiSearch
Primer Design and Search Tool [48,49]. The following
thermocycler program was used for amplification: 1 cycle
50°C, 2 min; 95°C, 12 min; and 40 cycles: 95°C, 20 sec;
56°C, 30 sec; 72°C, 1 min. For control amplifications of
the DBC1 locus the following primers were used: forward
primer TAT GCG CAC GAG CAT CCA, reverse primer TAC
GTA GAG AAG CTC TTG CTT, with conditions of amplifi-
cation being identical to the above.
PCR product cloning
Bisulfite PCR products were cloned using a Strataclone™
PCR cloning kit (Stratagene, La Jolla CA (catalog #
240205)), according to the kit protocol. Colony screening
was conducted using the colony PCR procedure, andBMC Molecular Biology 2008, 9:68 http://www.biomedcentral.com/1471-2199/9/68
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clones containing the correct insert were sequenced at the
UW Biotechnology Center DNA Sequencing Laboratory.
Surface preparation
Glass cover slips (22 × 22 mm, Fisher's Finest, Fisher Sci-
entific) were cleaned and derivatized according to previ-
ously published protocols [17].
DNA mounting, overlay, digestion and staining
DNA molecules were mounted on derivatized glass sur-
faces via capillary action utilizing a microfluidic device
[33]. To provide a sizing standard, bacteriophage DNA
was co-mounted with genomic DNA. A thin layer of acry-
lamide (3.3% containing 0.02% Triton X-100 [Sigma])
was applied to each surface. Following application the acr-
ylamide overlay was washed twice for 2 min with 400 μl
of TE and once with 200 μl of digestion buffer for the
same amount of time. The restriction digest was per-
formed by adding to each surface 200 μl of restriction
buffer (NEB buffer 2) supplemented with 20 units of
either NheI (NEB) or StuI (NEB) restriction enzymes. The
surfaces were then incubated for 2 hr at 37°C in a humid-
ified chamber.
For two enzyme, human optical maps, surfaces were first
treated for 2 hr at 25°C with 200 μl of restriction buffer
(NEB buffer 3) containing 20 units of the restriction
enzyme SwaI (NEB). The first mixture was aspirated off,
and 200 μl of restriction buffer (NEB buffer 3) with 20
units of the restriction enzyme EagI (NEB) was added. The
surface was then incubated in a 37°C humidity chamber
for an additional 2 hr. Following digestion, the surfaces
were washed twice with 500 μl of TE for 5 minutes. The
surfaces were mounted onto a glass slide with 12 μl of 0.2
μM YOYO-1 solution (containing five parts YOYO-1 solu-
tion and 95 parts of β-mercaptoethanol in TE 20% v/v).
The samples were sealed with nail polish and incubated in
the dark for 20 min allowing the staining dye to diffuse.
Image acquisition and processing
Surface mounted DNA samples were imaged in a fully
automated fashion with a 63× objective (Zeiss) and a high
resolution digital camera [23,33]. Co-mounted bacteri-
ophage molecules were used to determine both the digest
rate and to provide a sizing standard for integrated fluo-
rescence intensity measurements [20]. Machine vision
software (Pathfinder) was used to create optical maps
from imaged molecules [32,33].
Pairwise alignments of optical maps
Optical maps were aligned to the in silico maps using pair-
wise alignment. Optimal alignments were found using an
implementation of the Smith-Waterman algorithm for
restriction maps with a heuristic scoring function moti-
vated by a likelihood ratio test for the distinguishing spu-
rious alignments from optical mapping error [34,41]. An
alignment of two maps is a pairing of the cut sites of the
two maps. Each pair of cut sites is given a numerical score.
This score is positive if the adjacent fragment lengths are
of comparable length. The score is penalized as the
lengths differ and also if the adjacent fragment pairs have
cut site differences. The score of an alignment of two maps
is the sum of the scores of their aligned pairs of cut sites.
For two maps of lengths n and m respectively, 2 nm align-
ments are possible. The Smith-Waterman algorithm is an
efficient method for finding that alignment with the high-
est score. By definition, any two maps will have a highest-
scoring alignment. However, that alignment may be spu-
rious and not biologically meaningful. Because there is no
way to guarantee that an alignment is or is not spurious,
one needs to use statistical methods for excluding spuri-
ous alignments from the assembly inputs.
Optical map assembly
The optical map assembler was used to construct de novo
E. coli consensus maps [19-21,39,40]. The assembler uses
a dynamic programming algorithm to assemble individ-
ual optical maps into contigs. The assembler has built in
error checking and correction features, as well as a number
of user defined variables. For the AluI methylated E. coli
NheI de novo optical map the assembly T value was 0.001;
the false circular probability was set to 0.01. The final
quality score reported as false circularization probability
(FP) was 0.057. For the Dcm methylated StuI optical map
assembly, a dynamic range of T values was used:
0.000001, 0.00001, 0.0001 and a false circular probabil-
ity of 0.01 was used. The final quality score for the contig
was FP = 0.015.
Optical map contig (consensus) to in silico map alignment
The map assembler was used to align contig consensus
optical maps to sequence derived in silico maps [39,40].
De novo maps were aligned to the in silico map with very
stringent parameters in regards to sizing error and the
probability of fragments missing in the de novo maps. In
the resulting alignment, sites of DNA methylation in the
de novo map appeared as missing cuts in reference to the
in silico maps. The in silico map was used as a seed and the
following map assembler parameters were used; a
dynamic T value range 0.001; 0.01; 0.1, false circular
probability of 0.1, the probability of missing 1 kb frag-
ment was set to 0.
Optical map alignment and assembly–two enzymes
Optical maps generated with two enzymes (SwaI and
EagI) were pairwise aligned to an in silico map of the
human genome. Optimal alignments were found using an
implementation of the Smith Waterman algorithm for
restriction maps with a heuristic scoring function moti-
vated by a likelihood ratio test for the distinguishing spu-BMC Molecular Biology 2008, 9:68 http://www.biomedcentral.com/1471-2199/9/68
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rious alignments from optical mapping error [34,41]. The
following algorithms were used: (1) optical maps were
aligned to a SwaI in silico map using our lab's default pair-
wise alignment parameters; (2) optical maps were aligned
to a SwaI in silico map, with a lowered alignment penalty
for extra cuts; (3) optical maps were aligned to a two
enzyme (SwaI and EagI) in silico map of the human
genome, with a lowered penalty for missing cuts. Optical
maps that aligned using one of the above were pooled
into one map set. The composite map set was used to pro-
duce contigs with map assembler. The resulting contigs
were aligned to an in silico SwaI map of the human
genome based on build 35 (hg17) [50].
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